Langerhans cells (LCs) are dendritic cells (DCs) localized to the epidermis. They should be the first antigenpresenting cells to encounter squamous cell carcinoma (SCC). The aim of this study was to investigate the ability of LCs isolated from human SCC to induce T-cell proliferation and polarization. We investigated the ability of LCs from SCC and peritumoral skin to induce T-cell proliferation and polarization. We also studied the effect of SCC supernatant on the ability of LCs from normal skin, in vitro-generated LCs, and DCs to activate and polarize T cells. LCs from SCC were stronger inducers of allogeneic CD4 þ and CD8
INTRODUCTION
Dendritic cells (DCs) are the most potent antigen-presenting cells, comprise a variety of subsets, and serve as master regulators of adaptive immunity (Fricke and Gabrilovich, 2006; Steinman and Banchereau, 2007) . Because of their potential to elicit tumor-specific T-cell responses, it is generally accepted that DCs have key roles in cancer immune surveillance (Gottfried et al., 2008) . Numerous studies have demonstrated that DCs often infiltrate various human tumors (Vicari et al., 2002; Talmadge et al., 2007; Chaput et al., 2008) . However, DCs from some cancers are functionally compromised (Pinzon-Charry et al., 2005; Fricke and Gabrilovich, 2006; Bennaceur et al., 2008; Chaput et al., 2008; Gottfried et al., 2008) . Many studies have demonstrated decreased ability of DCs from human cancer to stimulate T cells and induce IFN-g (Enk et al., 1997; Gabrilovich et al., 1997; Nestle et al., 1997; Troy et al., 1998; Curiel et al., 2003; Perrot et al., 2007) . Hence, it has been postulated that dysfunction of DCs, induced by the tumor microenvironment, may allow tumors to escape immune surveillance (Pinzon-Charry et al., 2005) .
The deficit of endogenous DCs frequently observed in cancer patients led to the use of ex vivo-generated DCs as carriers of cancer vaccines (Pinzon-Charry et al., 2005; Kalinski et al., 2009) . Clinical trials using ex vivo-generated DCs have occasionally yielded significant tumor regression (Steinman and Banchereau, 2007; Kalinski et al., 2009) . However, objective clinical benefits are very limited, arguing for the need to improve the design of DCbased vaccines (Rosenberg et al., 2004; Banchereau and Palucka, 2005) . In particular, even the appropriate DC subset for clinical use remains undefined. Given the functional differences among DC subsets, further understanding of the biology of each DC subset in the complex tumor-associated environment is crucial (Shurin and Lotze, 2009 ; Ueno et al., 2010).
The skin immune system harbors a rich network of DCs, mainly composed of epidermal Langerhans cells (LCs) and dermal myeloid DCs. We and others have demonstrated that dermal myeloid DCs, associated with cutaneous basal cell carcinoma and squamous cell carcinoma (SCC), are deficient in their ability to stimulate T cells (Nestle et al., 1997; Bluth et al., 2009) . We have previously shown that the number of LCs is significantly decreased in SCC, which corroborates previous observations by others (Galan and Ko, 2007; Takahara et al., 2009) . However, the functional significance of LCs in human cutaneous SCC remains undefined.
As cutaneous SCC is a malignant proliferation of epidermal keratinocytes, LCs should be the first antigen-presenting cells to encounter tumor antigens. This prompted us to study the functional properties of LCs in cutaneous SCC. Here, we report observations, which to our knowledge are previously unreported, relating to the potential value of using LCs for cancer immunotherapy.
By using human SCC specimens, we show that epidermal LCs, and in vitro-generated LCs, can be activated to elicit desirable type 1 immunity. This is in direct contrast to what we previously found for myeloid DCs in SCC, and thus demonstrates the unique biology of LCs, which can be exploited for therapeutic advantage. Our findings provide a new rationale for harnessing both in vivo-and in vitro-generated LCs for cancer treatment. Manipulation of LCs generated from human blood precursors to drive antitumor response may be particularly useful in adoptive immunotherapy.
RESULTS
LCs from human SCC are more mature compared with LCs from peritumoral nonlesional skin As DC maturation is a key event in the induction of the immune responses, we first characterized the maturation status of LCs from SCC by analyzing the expression of maturation makers. HLA-DR þ CD207 þ cells from epidermal cell suspensions derived from SCC and peritumoral nonlesional (PTNL) skin were defined as LCs and evaluated for CD40, CD80, CD83, and CD86 expression by flow cytometry. SCC-derived LCs expressed higher levels of CD40, CD80, CD83, and CD86 compared with LCs from patientmatched PTNL skin (Figure 1 ). HLA-DR þ CD207 À cells were observed in 50% of cases. These cells did not express CD40, CD83, CD86, or common leukocyte antigen CD45, and were thus likely to be tumor cells.
LCs from human SCC are more powerful stimulators of allogeneic CD4
þ and CD8 þ T-cell proliferation than those from PTNL skin
To explore whether the more mature phenotype of SCCderived LCs was linked to their capacity to stimulate T-cell proliferation, we performed mixed leukocyte reactions (MLRs). Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled allogeneic total T cells from peripheral blood were cocultured with FACS-sorted HLA-DR þ CD207 þ LCs from either SCC tumor nests or patient-matched PTNL skin for 7 days; T-cell proliferation was then assessed by flow cytometry. We set gates on live CD3 þ CD4 þ and CD3 þ CD8 þ cells for analysis and evaluated T-cell proliferation by CFSE dilution. As shown in Figure 2a , LCs from SCC induced significantly higher levels of allogeneic CD4 þ and CD8 þ T-cell proliferation than those from PTNL skin. Representative FACS histograms are shown in Figure 2b .
LCs from human SCC induce type 1 T-cell response more efficiently than those from PTNL skin Next, we examined cytokine profiles of T cells activated by LCs from SCC and those from PTNL skin. We focused on the cytokines associated with specific T helper (Th) cell subtypes, including IFN-g (Th1), IL-4 (Th2), IL-17 (Th17), and IL-22 (Th22). Total allogeneic T cells cultured with FACS-sorted LCs for 7 days were subsequently activated by phorbol 12-myristate 13-acetate and ionomycin for 4 hours in the presence of brefeldin A, followed by intracellular cytokine staining. The percentages of T cells producing IFN-g (Th1), IL-4 (Th2), IL-17 (Th17), and IL-22 (Th22) are shown in Figure  2c . LCs from SCC induced significantly greater percentages of IFN-g-producing cells than those from PTNL skin in both CD4 þ and CD8 þ T cells. The frequencies of CD4 þ and CD8 þ T cells producing IL-4, IL-17, and IL-22 were not different between the two groups. The percentages of IFN-producing T cells did not vary with numbers of LCs isolated per skin sample. Representative FACS plots of cytokine production by proliferating T cells are shown in Figure 2d .
LCs from SCC show a mixed gene expression profile with both immune activation and immune tolerance genes
We were interested in determining the genomic signature of SCC-associated LCs, as they were unexpectedly more stimulatory than those from PTNL skin. Gene array analysis was performed to compare LCs isolated from SCC and those from patient-matched PTNL skin with verification of FACS analysis (see Supplementary Results and Supplementary Figure S1 online). We found that molecules associated with DC maturation and activation, including signal transducer and activator of transcription (STAT)-4, IL-15, LY75/CD205, CD80, IL-2RA/CD25, STAT-5B, and STAT-5A, were upregulated exclusively in SCC-derived LCs (Supplementary  Table S1 online). Interestingly, molecules that can be involved in immune tolerance, such as CD200 and receptor activator of NF-kB, were also upregulated in LCs from SCC. Three probes corresponding to CLEC2D showed increased expression in SCC-associated LCs (3.498-to 4.768-fold, Po0.0001 À0.00.4, Supplementary Table S2 online). CLEC2D has been linked to IFN-g via interaction with its receptor, CD161, which is expressed on T cells (Aldemir et al., 2005) .
SCC supernatant enhances CD4
þ and CD8 þ T-cell proliferation induced by LCs
As LCs should present tumor antigens to T cells in the context of the SCC-associated environment in vivo, we were also interested in how soluble factors released from the SCC microenvironment affect the interaction of LCs and T cells. To simulate the interaction of LCs and T cells in the SCC microenvironment, SCC culture supernatants were prepared and added to MLR experiments. FACS-sorted LCs from normal epidermis and CFSE-labeled allogeneic total T cells from peripheral blood were cocultured for 7 days in the presence or absence of 25% tumor supernatant (TSN) from SCC; then, T-cell proliferation was assessed as described above. Interestingly, as shown in Figure 3a , TSN applied to MLR assays significantly augmented the proliferation of both CD4 þ and CD8 þ T cells triggered by LCs. When T cells were cultured in the presence of TSN without LCs, their proliferation was not observed (data not shown). Representative FACS histograms are shown in Figure 3b .
SCC supernatant facilitates the generation of a broad range of CD4 þ T cells, as well as IFN-c-producing
cells among T cells expanded by LCs
We also investigated the cytokine profile of T cells stimulated by LCs in the presence or absence of TSN as described above. As shown in Figure 3c , the addition of TSN to MLR culture significantly increased the frequencies of the cells producing IFN-g, IL-4, IL-17, and IL-22 among proliferating CD4 þ T cells. With respect to CD8 þ T cells, only the frequency of the cells producing IFN-g was increased by TSN. Representative FACS plots of cytokine production by proliferating T cells are shown in Figure 3d .
SCC supernatant enhances the proliferation of CD4
þ and CD8 þ T cells induced by in vitro-generated LC-type DCs, whereas it suppresses T-cell proliferation driven by monocyte-derived DCs For in vitro-generated DC-based vaccine therapy for cancer patients, DCs are prepared by the culture of CD34 
HPCs contain CD1a
þ CD14 À LC-type DCs. Therefore, we were further interested in whether CD34
þ HPC-derived LC-type DCs were also capable of stimulating T cells effectively in the tumor-associated environment. We assessed the capability of the LC-type DCs to activate allogeneic T cells in the presence of SCC supernatant as above. We also used monocyte-derived DCs from the same donors for comparison. As shown in Supplementary Figure S2 online, we were able to obtain CD1a þ CD14 À cells with an LC phenotype by culturing CD34
þ HPCs with GM-CSF, TNF-a, and fms-like tyrosine kinase 3 ligand. Monocyte-derived DCs were obtained by culturing monocytes with GM-CSF and IL-4. Consistent with our observations from normal epidermal LCs, the presence of TSN in MLR culture significantly enhanced the proliferation of both CD4 þ and CD8 þ T cells triggered by LC-type DCs (Figure 4a ). On the other hand, the proliferation of both CD4 þ and CD8 þ T cells induced by monocyte-derived DCs was significantly suppressed by adding TSN to culture. Representative FACS histograms are shown in Figure 4b . SCC supernatant enhances type 1 T-cell response elicited by in vitro-generated LC-type DCs, but suppresses that induced by monocyte-derived DCs
The cytokine profiles of T cells stimulated by LC-type DCs and monocyte-derived DCs in the presence or absence of SCC supernatant were examined as well. As shown in Figure  4c , the percentages of IFN-g-producing cells among proliferating CD4 þ and CD8 þ T cells stimulated by LC-type DCs were significantly increased by the presence of TSN in culture. The addition of TSN also elevated the frequency of IL-17-producing CD4 þ T cells activated by LC-type DCs. In contrast, the presence of TSN in culture significantly reduced the percentages of the cells expressing IFN-g among proliferating CD4
þ and CD8 þ T cells stimulated by monocyte-derived DCs. Thus, type 1 immune response induced by LC-type DCs was promoted by TSN, whereas that induced by monocyte-derived DCs was attenuated. Representative FACS plots of cytokine production by proliferating T cells are shown in Figure 4d . Overall, monocyte-derived DCs were less able than LCs to stimulate T cells than LCs with media alone (Supplementary Figure S3 online). In another series of experiments, LCs or DCs, generated in vitro, were pretreated with TSN and extensively washed before culturing with allogeneic T cells. TSN pretreatment enhanced the ability of in vitro-generated LCs to drive T-cell proliferation, and it suppressed the ability of in vitro-generated DCs to drive allogeneic T-cell proliferation (Supplementary Figure S4 online ).
SCC supernatants contain cytokines that suppress myeloid DCs
Abundant evidence indicates that immunosuppressive cytokines in the tumor microenvironment impair DC differentiation and function (Zou, 2005; Fricke and Gabrilovich, 2006) . Indeed, in a previous study, we have shown high mRNA expression of IL-10, vascular endothelial growth factor (VEGF), and transforming growth factor-b 1 (TGF-b 1 ) in cutaneous SCC specimens (Bluth et al., 2009) . To identify the cytokine milieu of cutaneous SCC in more detail, we screened TSNs from SCC specimens for the production of cytokines. The amounts of IFN-g, IL-1b, IL-2, IL-6, IL-8, IL12p70, TNF-a, GM-CSF, IL-10, VEGF, and TGF-b 1 in TSNs were measured by an electrochemiluminescence-based system (n ¼ 12). As shown in Table 1 , SCC supernatants contained significant levels of IFN-g (9.8 ± 2.4 pg ml ; 12 out of 12 samples; mean± SEM for all). We could not detect these cytokines in culture media used for culturing tumor samples (n ¼ 3). Of 12 TSN samples, 11 had higher concentrations of TGF-b 1 (33.5 ± 4.4 pg ml -1 ) than the media used for the culture (baseline level). Thus, TSNs from cutaneous SCCs Abbreviations: ND, not detected; SCC, squamous cell carcinoma; TGF-b, transforming growth factor-b; TNF-a, tumor necrosis factor-a; TSN, tumor supernatant; VEGF, vascular endothelial growth factor. Size-comparable specimens of whole-tissue SCC specimens were cultured for 24 hours, and the contents of IFN-g, IL-1b, IL-2, IL-6, IL-8, IL-12p70, TNF-a, GM-CSF, IL-10, VEGF, and TGF-b 1 in the supernatants were analyzed using an electrochemiluminescence-based method. Media 1-3 represent the media used for the culture of SCC specimens.
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carry tumor immunosuppressive cytokines, such as VEGF, TGF-b 1 , IL-10, and IL-6.
DISCUSSION
The induction of effective anticancer response depends on innate and adaptive immunity coordinated by DCs (Pinzon-Charry et al., 2005) . However, the dysfunction of DCs in tumor tissue has been noted in various types of cancer. Similar findings have also been reported in the blood-circulating DCs from cancer patients (Almand et al., 2000 (Almand et al., , 2001 Della Bella et al., 2003) . These observations suggest that DC dysfunction may be a systemic event rather than a phenomenon simply confined to the local tumor microenvironment (Pinzon-Charry et al., 2005; Bennaceur et al., 2008) . We previously showed that the T-cell stimulatory capacity of myeloid DCs from human cutaneous SCC is considerably impaired (Bluth et al., 2009) . In this study, we evaluated the function of a different DC subset, epidermal LCs, isolated from cutaneous SCC.
In sharp contrast to myeloid DCs, LCs from SCC were more powerful stimulators of allogeneic CD4 þ and CD8 þ T-cell proliferation than LCs from PTNL skin. This result was consistent with the more mature phenotype of SCCderived LCs. Furthermore, LCs from SCC were superior to those from PTNL skin in polarizing CD4 þ and CD8 þ T cells to produce IFN-g, a key cytokine required for antitumor immunity. Thus, contrary to cancer-associated myeloid DCs, LCs in SCC exhibited enhanced ability to stimulate T-cell proliferation and drive desirable type 1 T-cell responses.
In vitro, the proliferation of both CD4 þ and CD8 þ T cells driven by LCs from normal skin was augmented in the presence of TSN. TSN was stimulatory, despite the fact that we found it was rich in DC-suppressive cytokines. This is consistent with the results obtained from the comparison between SCC-derived LCs and those from PTNL skin. The effect of TSN was specific to IFN-g induction by CD8 þ T cells, and did not lead to induction of CD8 þ T cells producing IL-4, IL-17, or IL-22. The ability of epidermal LCs to both induce T-cell proliferation and drive IFN-g response was enhanced even in the presence of tumorderived soluble immunosuppressive mediators; this implies that T-cell proliferation and type 1 immune response based on LC/T-cell interactions are not vulnerable to the immunosuppressive SCC microenvironment. This is consistent with the report that the T-cell stimulatory ability of LCs is not affected by melanoma cell-derived factors (BerthierVergnes et al., 2001) . LCs isolated from the lymph nodes of tumor-bearing mice are also shown to be fully competent in stimulating T-cell proliferation (Ishida et al., 1998) . Taken together, these findings support the concept that epidermal LCs seem to be a unique DC subset that is resistant to a predominantly immunosuppressive tumor environment.
Nevertheless, patients' immune systems fail to eradicate SCC tumors, despite the enhanced ability of SCC-derived LCs to induce strong type 1 immunity ex vivo. This implies that tumor-specific immunity elicited by LCs is suboptimal in situ.
One plausible explanation for this discrepancy is the relatively low number of LCs in the tumor nests. We and others have observed lower numbers of LCs in the SCC microenvironment (Galan and Ko, 2007; Bluth et al., 2009; Takahara et al., 2009) . We found fewer CD1a þ and Langerin þ cells infiltrating SCC tumor nests and even fewer Langerhans cells in adjacent nontumor-bearing skin (Bluth et al., 2009) . Other potential mechanisms include defective recognition, internalization, processing, and presentation of tumor antigens by LCs, as well as a deficit in their migration to gain access to T cells. Physical contact of LCs with immunosuppressive cells such as regulatory T cells and the presence of myeloid-derived suppressor cells in the tumor microenvironment should also be taken into consideration.
As isolated LCs are immunologically active, they may have potential in LC-based SCC immunotherapy. One of the major strategies for DC-based cancer immunotherapy is the transfer of DCs generated from precursors under ex vivo tumor-free conditions (Schuler et al., 2003; Steinman and Banchereau, 2007; Banchereau et al., 2009) . Most studies use DCs induced from peripheral blood monocytes (Nestle et al., 1998; Thurner et al., 1999; Berntsen et al., 2006; Palucka et al., 2006) . DCs derived from CD34
þ HPCs, containing LCtype DCs, have also been used for this purpose (Banchereau et al., 2001; Di Nicola et al., 2004) . We demonstrated that the ability of LC-type DCs to expand CD4 þ and CD8 þ T cells and drive IFN-g response was significantly enhanced in the presence of SCC-derived factors; in contrast, the activity of monocyte-derived DCs was suppressed by SCCderived factors. These results are consistent with previous reports that LC-type DCs or total DCs derived from CD34 þ HPCs are superior to monocyte-derived DCs in the induction of antigen-specific CD8 þ T cells (Mortarini et al., 1997; Ferlazzo et al., 1999; Ratzinger et al., 2004) . Both SCCderived LCs and LC-type DCs showed the ability to stimulate T-cell proliferation and promote desirable type 1 immune response. As the tumor microenvironment may suppress myeloid DC activity (Vicari et al., 2002) , our results support an idea that in vitro-generated LCs may be suitable for cancer immunotherapy (Banchereau et al., 2001) . Although the mechanisms underlying the observed differences between the two types of DC remain undefined, we believe our data lend a new rationale to the use of LC-type DCs in cancer vaccine therapy.
Another promising strategy for DC-based cancer immunotherapy is the targeted delivery of tumor antigens to in vivo DCs, either by using anti-DC antibodies such as CD205 and CD207 or by simple and direct application on barrierdisrupted skin (Steinman and Banchereau, 2007; Flacher et al., 2009; Romani et al., 2010; Stoitzner et al., 2010) . Skin DCs, especially LCs, are targeted in this approach because of relatively easy access. Indeed, the pivotal role of LCs in the protecting effect of epicutaneous immunization in tumorbearing mice has been shown using the LC-depletion model (Stoitzner et al., 2008) . Considering that myeloid DCs can be systemically impaired in cancer patients, our observation that epidermal LCs in tumor-associated environment acted as even more powerful antigen-presenting cells also supports the validity of this second maneuver exploiting in vivo LCs.
The immune microenvironment associated with cutaneous SCC is a highly complex milieu comprising opposing forces driving activation of one DC type and suppression of another. The observed contrasting effects of TSN may be the result of the combined effect of a wide range of soluble mediators that are both stimulatory and inhibitory. The simultaneous upregulated gene expression of both immunostimulatory and immunosuppressive molecules in SCC-derived LCs might reflect this complicated tumor microenvironment as well. Our results demonstrate that the cancer microenvironment can affect distinct DC subtypes in totally different ways.
One potential explanation for our findings may reside in the CLEC2D/CD161 axis. CLEC2D is a C-type lectin that has been linked to IFN-g induction via interaction with CD161 on T cells (Aldemir et al., 2005) . Maggi et al. (2010) showed that CD161 is expressed by Th1, Th2, Th0, and Th17 cells and is inducible by RORC. We found that CLEC2D was overexpressed in LCs from SCC (3.5-to 4.8-fold, Po0.004 À0.0001) based on expression of probes 220132-s, 233500_x and 23522 (Supplementary Table S1 online). Thus, it may be that LC expression of CLEC2D may be important in initiating type 1 antitumor immunity. The mechanisms governing these processes will be the focus of ongoing work by our group.
In conclusion, we have shown the evidence that human LCs act as powerful inducers of type 1 T-cell response in the cancer microenvironment. Our findings provide a new rationale to the use of LCs for DC-based cancer immunotherapy, and thus pave the way to new cancer immunotherapy based on LC function.
MATERIALS AND METHODS
The study was approved by the institutional review board of Weill Cornell Medical College and the Rockefeller University. Written informed consent was obtained before enrolling patients to participate in this study. The study was performed in adherence with the Declaration of Helsinki Principles.
Skin sample preparation for flow cytometry
Tumors of cutaneous SCC and site-matched PTNL skin were obtained at surgery, and normal skin was obtained as the discarded product of dermatologic and plastic surgery. All SCCs were primary stage 1 SCCs from sun-exposed areas of the head and neck. Epidermal single-cell suspensions were prepared using Dispase II (Roche Diagnostics, Mannheim, Germany) and trypsin-ethylenediamine tetraacetic acid (Invitrogen, Carlsbad, CA) as described previously (Fujita et al., 2009) .
Flow cytometry

FACS of epidermal HLA-DR
þ CD207 þ LCs, as well as FACS phenotyping of epidermal LCs and in vitro-generated LC-type DCs, was performed as previously described (Fujita et al., 2009) . Antibodies used are outlined in Supplementary Table S2 online.
Generation of LC-type DCs in vitro
LC-type DCs were obtained by culturing CD34 þ HPCs with GM-CSF (100 ng ml -1 ; R&D Systems, Minneapolis, MN), fms-like tyrosine kinase 3 ligand (100 ng ml -1 ; R&D Systems), and TNF-a (10 ng ml -1 ; R&D Systems) for 8 days as previously described (Fujita et al., 2009 ). On day 8, CD1a þ CD14 À LC-type DCs were sorted on a FACSAria (BD Biosciences, San Jose, CA).
Generation of monocyte-derived conventional DCs
Monocyte-derived DCs were obtained by culturing peripheral blood mononuclear cells with 25 ng ml -1 IL-4 and 100 ng ml -1 GM-CSF (both from R&D Systems) for 8 days as previously described (Fujita et al., 2009 ). On day 8, live and forward scatter-and side scatter-high cells were sorted on a FACSAria for purification of DCs.
MLR assay
The MLR assay was performed as previously described (Fujita et al., 2009) . For the evaluation of cell proliferation, T cells were labeled with CFSE using the Vybrant CFDA SE Cell Tracer Kit (Invitrogen/ Molecular Probes) as previously described (Fujita et al., 2009 ).
Intracellular cytokine staining
T cells stimulated with allogeneic LCs/DCs for 7 days were restimulated for 4 hours with 25 mg ml -1 phorbol 12-myristate 13-acetate and 2 mg ml -1 ionomycin in the presence of 10 Mg ml -1 brefeldin A (all from Sigma Aldrich, St Louis, MO) at 37 1C. Intracellular cytokine staining was then performed as previously described (Fujita et al., 2009) . Antibodies used are outlined in Supplementary Table S1online . Expression of each molecule was analyzed in activated (forward scatter-and side scatter-high cells) T cells.
Collection of TSNs
Freshly excised whole-tissue specimens of cutaneous SCC of uniform size (B1.5 cm 2 ) were cut into small pieces with a scalpel and incubated at 37 1C in a six-well plate in 2 ml of complete medium. Medium was harvested after 24 hours of culture and centrifuged at 1,500 r.p.m. for 5 minutes, and then supernatants were collected and run over a 0.22-mm Millex-GP filter (Millipore, Bedford, MA) and stored at À20 1C. The supernatants were added to the MLR culture in a 1:4 dilution as described previously (Enk et al., 1997) . 
